Summary
The effect of somatostatin (SRIF: 10 ug/min during 120 min) on serum prolactin (PRL)
levels was studied in eleven patients with hyperprolactinemia of varying causes: 2
patients with acromegaly; 2 with primary hypothyroidism; 4 with prolactinoma and 3
with drug (sulpiride) induced hyperprolactinemia.
During SRIF infusion, no significant change in PRL levels was observed in any of the
4 groups studied except in one female patient with a prolactinoma.
The biological activity of SRIF was demonstrated by the significant inhibition (P
< 0.05) of insulin levels seen in all 11 patients (52% fall in relation to basal)
without simultaneous modification of glycemia.
These data suggest that SRIF does not decrease PRL secretion in most patients with
hyperprolactinemia.
Key-Words
Somatostatin
-
Hyperprolactinemia
-
Drug Induced
-
Hypothyroidism
-
Acromegaly
-
Prolactinoma
